Your email has been successfully added to our mailing list.

×
0 0.00193699910413792 -2.42124888018825E-05 -0.00244546136897422 0.00602890971162919 0.00723953415171536 0.0266095251930945 0.00845015859180153
Stock impact report

ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment [MarketWatch]

ARCA biopharma, Inc. (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
Company Research Source: MarketWatch
Shares of ARCA Biopharma Inc. gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug Administration for its mid-stage experimental COVID-19 treatment. ARCA plans to launch a Phase 2b clinical trial enrolling 100 hospitalized COVID-19 patients next month, and it anticipates that the first round of topline data from the study will be available in the second quarter of next year. ARCA's stock is down 31.9% so far this year, while the S&P 500 has gained 10.1%. Show less Read more
Impact Snapshot
Event Time:
ABIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
ABIO alerts

from News Quantified
Opt-in for
ABIO alerts

from News Quantified